Literature DB >> 16339562

E2 of hepatitis C virus inhibits apoptosis.

Song Hee Lee1, Yoon Ki Kim, Chon Saeng Kim, Su Kyoung Seol, Joonhyun Kim, Sungchan Cho, Young Lan Song, Ralf Bartenschlager, Sung Key Jang.   

Abstract

Hepatitis C virus (HCV) is the major causative agent of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, and can be involved in very long chronic infections up to 30 years or more. Therefore, it has been speculated that HCV possesses mechanisms capable of modulating host defense systems such as innate and adaptive immunity. To investigate this virus-host interaction, we generated HCV replicons containing various HCV structural proteins and then analyzed the sensitivity of replicon-containing cells to the apoptosis-inducing agent, TRAIL. TRAIL-induced apoptosis was monitored by cleavage of procaspase-3 and procaspase-9 as well as that of their substrate poly(ADP-ribose) polymerase. TRAIL-induced apoptosis was inhibited in cells expressing HCV E2. Moreover, expression of HCV E2 enhanced the colony forming efficiency of replicon-containing cells by 25-fold. Blockage of apoptosis by E2 seems to be related to inhibition of TRAIL-induced cytochrome c release from the mitochondria. Based on these results, we propose that E2 augments persistent HCV infection by blocking host-induced apoptosis of infected cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339562     DOI: 10.4049/jimmunol.175.12.8226

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants.

Authors:  Eu Jin Lim; Ruth Chin; Peter W Angus; Joseph Torresi
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

2.  New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94.

Authors:  Min Hyeok Jee; Ka Young Hong; Ji Hoon Park; Jae Seung Lee; Hee Sun Kim; Song Hee Lee; Sung Key Jang
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 3.  Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer.

Authors:  D R McGivern; S M Lemon
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

Review 4.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 5.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

6.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Authors:  D Lecis; C Drago; L Manzoni; P Seneci; C Scolastico; E Mastrangelo; M Bolognesi; A Anichini; H Kashkar; H Walczak; D Delia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

7.  Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway.

Authors:  Lin Deng; Tetsuya Adachi; Kikumi Kitayama; Yasuaki Bungyoku; Sohei Kitazawa; Satoshi Ishido; Ikuo Shoji; Hak Hotta
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

8.  RNA-binding protein hnRNP D modulates internal ribosome entry site-dependent translation of hepatitis C virus RNA.

Authors:  Ki Young Paek; Chon Saeng Kim; Sung Mi Park; Jong Heon Kim; Sung Key Jang
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 9.  Coinfection with HIV-1 and HCV--a one-two punch.

Authors:  Arthur Y Kim; Raymond T Chung
Journal:  Gastroenterology       Date:  2009-06-21       Impact factor: 22.682

10.  HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice.

Authors:  Michael A Joyce; Kathie-Anne Walters; Sue-Ellen Lamb; Mathew M Yeh; Lin-Fu Zhu; Norman Kneteman; Jason S Doyle; Michael G Katze; D Lorne Tyrrell
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.